Accurately assessing treatment response and predicting recurrence in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy is challenging.
This study explores the use of circulating tumor DNA (ctDNA) and its combination with tumor markers (TM) for this purpose.
